The future of "omics" in hypertension

Currie, G. and Delles, C. (2017) The future of "omics" in hypertension. Canadian Journal of Cardiology, 33(5), pp. 601-610. (doi: 10.1016/j.cjca.2016.11.023) (PMID:28161100) (PMCID:5417769)

132427.pdf - Published Version
Available under License Creative Commons Attribution.



Despite decades of research and clinical practice the pathogenesis of hypertension remains incompletely understood and blood pressure is often suboptimally controlled. Omics technologies allow the description of a large number of molecular features and have the potential to identify new factors that contribute to blood pressure regulation and how they interact. In this review we will focus on the potential of genomics, transcriptomics, proteomics and metabolomics and explore their role in unravelling the pathophysiology and diagnosis of hypertension; prediction of organ damage and treatment response; and monitoring of treatment effect. Substantial progress has been made in the area of genomics where genome-wide association studies have identified more than 50 blood pressure-related single nucleotide polymorphisms and sequencing studies especially in secondary forms of hypertension have discovered novel regulatory pathways. In contrast, other omics technologies, despite their ability to provide detailed insights into the physiological state of an organism, have only more recently demonstrated their impact on hypertension research and clinical practice. The majority of current proteomic studies focuses on organ damage due to hypertension and may have the potential to understand the link between blood pressure and organ failure but also serve as biomarker for early detection of cerebrovascular or coronary disease. Examples include signatures for early detection of left ventricular dysfunction or albuminuria. Metabolomic studies have potential to integrate environmental and intrinsic factors and are particularly suited to monitor the response to treatment. We will discuss examples of omics studies in hypertension and explore the challenges related to these novel technologies.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Currie, Dr Gemma and Delles, Professor Christian
Authors: Currie, G., and Delles, C.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Canadian Journal of Cardiology
ISSN (Online):1916-7075
Published Online:07 December 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Canadian Journal of Cardiology 33(5):601-610
Publisher Policy:Reproduced under a creative commons license

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
617771BHF centre of excellenceRhian TouyzBritish Heart Foundation (BHF)RE/13/5/30177RI CARDIOVASCULAR & MEDICAL SCIENCES
593511SysVascChristian DellesEuropean Commission (EC)603288RI CARDIOVASCULAR & MEDICAL SCIENCES
573932PRIORITY: Intervention study for the prevention of diabetic nephropathyChristian DellesEuropean Commission (EC)279277RI CARDIOVASCULAR & MEDICAL SCIENCES
601881HOMAGE: Heart OMics in AGEingChristian DellesEuropean Commission (EC)305507RI CARDIOVASCULAR & MEDICAL SCIENCES